| Literature DB >> 19748579 |
Silvia M Estein1, María A Fiorentino, Fernando A Paolicchi, María Clausse, Jorge Manazza, Juliana Cassataro, Guillermo H Giambartolomei, Lorena M Coria, Vanesa Zylberman, Carlos A Fossati, Rune Kjeken, Fernando A Goldbaum.
Abstract
We have engineered the polymeric vaccine BLSOmp31 by decorating the highly immunogenic and decameric Brucella lumazine synthase with an exposed loop of the Brucella outer membrane protein Omp31. In the present study, we have immunized different groups of rams with the recombinant chimera rBLSOmp31 in two different adjuvants (Incomplete Freund Adjuvant-IFA and QUIL A) and with the plasmid pCIBLSOmp31 administered either by i.m. injection alone or by using electroporation. In addition, we have used a heterologous prime-boost strategy consisting of repeated pCIBLSOmp31 electroporation priming followed by a single protein boost. Both, chimera rBLSOmp31 in IFA and the prime-boost strategy induced the highest IgG specific antibodies with bacteriolytic activity. While electroporation-enhanced humoral immune responses as compared to pCIBLSOmp31 injection alone, the highest levels of specific IFN-gamma and protection against bacterial challenge were achieved with prime-boost (76%) and chimera rBLSOmp31 in IFA (63%). Taken together these results strongly support the usefulness of the chimera BLSOmp31 as a vaccine against Brucella ovis in ovine brucellosis.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19748579 DOI： 10.1016/j.vaccine.2009.08.097
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641